YONGIN, South Korea–(BUSINESS WIRE)–Feb 9, 2021– GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited financial results for the year ended 31 December 2019.
| Key Figures (1) | Full Year 2020 | Growth (2) |
| Total revenues | KRW 1,504.1 billion | +10.8% |
| Operating profit | KRW 50.2 billion | +20.6% |
| K-IFRS profit after taxation | KRW 89.1 billion | – |
| (1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations) | ||
| (2) Results and percentages compare full financial year 2019 |
Financial Highlights
- Delivered total revenue growth of 10.8% to KRW 1,504.1 billion (2019: 1,357.1 billion), and operation profit increased 20.6% to KRW 50.2 billion (2019: 41.7 billion) in the full year of 2020
- Unconsolidated revenues growth of 15.1%, driven by strong vaccines sale
- Strong subsidiaries performance continued, including Green Cross MS and Green Cross LabCell
- Local sales up 7.2% reflecting strong Vx and CHC segment performance
- International sales growth of 13.5% benefited from strong sales performance of Vx and Rx segment, and Flu and VZ Vx sales growth boosted overall export performance
- Achieved double-digit operation margin growth driven by increased overall local and international sales
- The performance for core businesses this year in line with where the company expect it to be, and will continue to focus on improving profitability as well as expending R&D investment for future business
Short-term R&D Milestones
- Hunterase ICV Japan regulatory decision in Q1 (Approved 22 January 2021)
- GreenGeneF China regulatory decision in Q1
- IVIG 10% US BLA submission in Q1
About GC Pharma GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company’s registered, legal name. This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005488/en/ CONTACT: Investor/Media Contact HyunGoo Kang +82 31 260 9382 [email protected] WooSub Shin +82 31 260 9397 [email protected] Jun +82 31 270 1505 [email protected] Kim +82 31 260 9392 [email protected] KEYWORD: SOUTH KOREA NORTH AMERICA CANADA ASIA PACIFIC INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: GC Pharma Copyright Business Wire 2021. PUB: 02/09/2021 03:24 AM/DISC: 02/09/2021 03:24 AM http://www.businesswire.com/news/home/20210209005488/en
